Search company, investor...

52 North Health

52north.health

Founded Year

2018

Stage

Grant | Alive

Total Raised

$2.83M

Last Raised

$1.42M | 5 days ago

About 52 North Health

52 North Health develops NeutroCheck which is a fully-integrated clinical, AI- and medical device-based system for people living with cancer. It is a point-of-care medical device that can be used by patients outside of the hospital to monitor their risk of neutropenic sepsis, a potentially life-threatening complication of chemotherapy. The company was formerly known as Neutrocheck It was founded in 2018 and is based in Cambridge, U.K.

Headquarters Location

Ideaspace West, The Hauser Forum 3, Charles Babbage Road

Cambridge, England, CB3 0GT,

United Kingdom

ESPs containing 52 North Health

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Biopharma Tech

Companies in this market offer blood testing and monitoring solutions, using digital biomarkers to improve patient care including for white blood cell level count, potassium balances, and blood coagulation. These solutions can help diagnose and treat blood-related illness and disease.

52 North Health named as Highflier among 9 other companies, including Levels, Loop Medical, and Signos.

Compete with 52 North Health?

Ensure that your company and products are accurately represented on our platform.

52 North Health's Products & Differentiators

    NeutroCheck solution

    An point-of-care and low cost fingerprick blood based in vitro diagnostic measuring neutrophil and sepsis marker levels, combined with a digital platform, to support clinical decision making for patients with suspected neutropenic sepsis

Research containing 52 North Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned 52 North Health in 1 CB Insights research brief, most recently on Oct 3, 2022.

Expert Collections containing 52 North Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

52 North Health is included in 6 Expert Collections, including Medical Devices.

M

Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

206 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

H

Health IT

7,901 items

C

Clinical Encounter Tech

899 items

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health

9,075 items

Startups recreating how healthcare is delivered

Latest 52 North Health News

Medtech startup 52 North Health scales up its mission to improve chemotherapy treatments

Nov 23, 2022

UK-based startup 52 North Health has just been awarded a €1.38 million (£1.2 million) grant from Innovate UK’s Smart Grant programme to bring safer and more effective care to patients undergoing chemotherapy. The medtech startup now plans to scale up its solution. Chemotherapy is a predominant form of cancer treatment that uses powerful chemicals to kill fast-growing cells in your body. It’s a treatment that aims to stop cancer cells from reproducing, which prevents them from growing and spreading in the body. For patients, chemotherapy can be a lifeline, but it is incredibly intense on the body, and for some, can even have fatal side-effects, namely, neutropenic sepsis (NS). Medtech company 52 North Health has developed a solution that aims to provide safer and more effective care to patients undergoing chemotherapy – NeutroCheck. Now, the startup has received a grant of €1.38 million (£1.2 million) to scale up development and hit key clinical milestones in order to bring the solution to patients. The details:  Follows a smaller award made to 52 North Health in January 2020 Composes of a 21-month collaboration between 52 North Health, Macmillan Cancer Support, UK Sepsis Trust, UnifAI Technology and Cambridge University Hospitals Umaima Ahmad, CEO of 52 North Health: “We are delighted to be collaborating with a brilliant and diverse set of partners on this important project which will further propel the value of the NeutroCheck solution and take it through its first clinical trial. This endorsement, our second Smart Grant from Innovate UK, is so important and allows our brilliant teams to focus on getting the NeutroCheck innovation to as many patients as possible throughout the country, so that we can make care for cancer patients across the NHS safer and more effective.”  It’s reported that every day, 3 people across England and Wales lose their lvies as a result of neutropenic sepsis (NS). Due to the fatality risk associated with NS, all patients undergoing chemotherapy who feel unwell are currently required to go directly to A&E, where they receive strong precautionary antibiotics and undergo a full blood test. Half of the patients are subsequently found not to be at risk, and many patients are not receiving their antibiotics quickly enough, endangering their chances of survival. Founded in 2018, 52 North Health want to change this outlook. The UK-based team has decoped NeutroCheck – a solution that composes a small, portable device and a digital platform, which assesses a patient’s risk at home through a blood finger-prick, helping doctors to accurately triage patients, with those at-risk prioritised, and allowing those not at-risk to stay home or instead be seen in the community. Tanya Humphreys, Head of Innovation Partnerships at Macmillan explained: “Neutropenic sepsis is a life-threatening condition and its monitoring can be very stressful for people with cancer undergoing chemotherapy. The NeutroCheck device has the potential to empower patients to take more control of their care and could have a significant positive impact on their quality of life. We are delighted to be supporting 52 North Health through this grant to ensure that people with cancer and their carers are meaningfully involved in the development of the Neutrocheck device. This is also a fantastic opportunity for us to collaborate with all the partners to make a big difference for people with cancer.” With this funding, the startup will be able to accelerate the process of bringing NeutroCheck to the patients who need it most. It’ll do so by collaborating with UnifAI Technology, whose AI-powered digital reader will be incorporated in the solution; Cambridge University Hospitals NHS Foundation Trust, where the trials will be held; and key charity partners in Macmillan Cancer Support and the UK Sepsis Trust, with the shared goal to provide safe and more effective care to patients undergoing chemotherapy. Dr Ron Daniels, Intensive Care Doctor and Founder and Chief Executive of the UK Sepsis Trust: “Although sepsis can affect people of any age, certain groups of people are at higher risk, and none more so than those undergoing chemotherapy. These patients are already going through enough trauma, so any device designed to guide as to whether or not they need to seek urgent hospital assessment is invaluable – not to mention the positive impact on a stressed NHS. We have partnered with 52 North Health because they have a true understanding of the need: the development of a device for use in the patient’s own home, which uses existing and highly relevant markers of risk is absolutely the right approach.”  Now, the startup plans to get ready for clinical validation. Dr Hugo Ford, lead cancer clinician for Cambridge University Hospitals, said: “This grant provides essential funding to perform the clinical validation study, which will begin next summer and involve about 250 patients. The results will underpin a submission for regulatory approval in the shape of UKCA and CE marking, which would allow us to test NeutroCheck using the device in an at-home setting for around 30 patients. This will in turn enable us to build an evidence base to support roll-out of the NeutroCheck solution across the NHS.” Tags

52 North Health Frequently Asked Questions (FAQ)

  • When was 52 North Health founded?

    52 North Health was founded in 2018.

  • Where is 52 North Health's headquarters?

    52 North Health's headquarters is located at Ideaspace West, The Hauser Forum 3, Charles Babbage Road, Cambridge.

  • What is 52 North Health's latest funding round?

    52 North Health's latest funding round is Grant.

  • How much did 52 North Health raise?

    52 North Health raised a total of $2.83M.

  • Who are the investors of 52 North Health?

    Investors of 52 North Health include Innovate UK Smart Grant, MedTech Innovator, Milltrust International, Cambridge Enterprise, Meltwind and 6 more.

  • What products does 52 North Health offer?

    52 North Health's products include NeutroCheck solution.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.